Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

A Phase I Study of Lintuzumab Ac225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML

Sameem Abedin, MD, Guru Subramanian Guru Guru Murthy, MBBS, Mehdi Hamadani, MD, Laura C. Michaelis, MD, Lyndsey Runaas, MD, Karen-Sue Carlson, MDPhD, Alexandra M. Harrington, MDMT(ASCP), Ehab L. Atallah, MD

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-137218

Published: 2020

Journal Articles

Immune Senescence and Exhaustion Correlate with Response to Flotetuzumab, an Investigational CD123×CD3 Bispecific Dart® Molecule, in Acute Myeloid Leukemia

Jayakumar Vadakekolathu, PhD, Tung On Yau, Sarah E. Church, PhD, Michael P. Rettig, PhD, Ibrahim Aldoss, MD, Geoffrey L Uy, MD, Norbert Vey, MD, Ashkan Emadi, MD, PhD, Peter H. Sayre, MDPhD, Roland B. Walter, MDPhDMS, Matthew C Foster, MD, Martha L. Arellano, MD, John E. Godwin, MD, Matthew J. Wieduwilt, MD PhD, Michael T. Byrne, DO, Laura C. Michaelis, MD, Patrick J. Stiff, MD, Matteo Giovanni Carrabba, MD, Patrice Chevalier, MD PhD, Emmanuel Gyan, MD PhD, Christian Recher, MD PhD, Anjali S Advani, MD, Martin Wermke, Harry P. Erba, Fabio Ciceri, MD, Geert Huls, MD PhD, Mojca Jongen-Lavrencic, MD PhD, Farhad Ravandi, MBBS, Antonio Curti, MDPhD, Max S. Topp, MD, John Muth, MS, Patrick Kaminker, PhD, Bob Lowenberg, MDPhD, Ivana Gojo, MD, Leo Luznik, MD, John F. DiPersio, MD PhD, Jan K Davidson-Moncada, MDPhD, Sergio Rutella, MDPhDFRCPath

Blood (2020) 136 (Supplement 1): 26–28.

https://doi.org/10.1182/blood-2020-134921

Published: 2020

Journal Articles

Prophylactic Ruxolitinib for Cytokine Release Syndrome (CRS) in Relapse/Refractory (R/R) AML Patients Treated with Flotetuzumab

Geoffrey L Uy, MD, Michael P. Rettig, PhD, Stephanie Christ, MS, Ibrahim Aldoss, MD, Michael T. Byrne, DO, Harry P. Erba, MD PhD, Martha L. Arellano, MD, Matthew C Foster, MD, John E. Godwin, MD, Farhad Ravandi, MBBS, Peter H. Sayre, MDPhD, Anjali S Advani, MD, Matthew J. Wieduwilt, MD PhD, Ashkan Emadi, MD, PhD, Laura C. Michaelis, MD, Patrick J. Stiff, MD, Martin Wermke, Norbert Vey, MD, Patrice Chevalier, MD PhD, Emmanuel Gyan, MD PhD, Christian Recher, MD PhD, Fabio Ciceri, MD, Matteo Giovanni Carrabba, MD, Antonio Curti, MDPhD, Geert Huls, MD PhD, Max S. Topp, MD, Mojca Jongen-Lavrencic, MD PhD, John Muth, MS, Teia Curtis, Mary Beth Collins, Erin Timmeny, Kuo Guo, MSc, Jian Zhao, PhD, Kathy Tran, Patrick Kaminker, PhD, Priyanka Patel, PharmD, Ouiam Bakkacha, MD, Kenneth Jacobs, MD, Maya Kostova, PhD, Jennifer Seiler, PhD RAC, Bob Lowenberg, MDPhD, Sergio Rutella, MDPhDFRCPath, Roland B. Walter, MDPhDMS, Ezio Bonvini, MD, Jan K Davidson-Moncada, MDPhD, John F. DiPersio, MD PhD

Blood (2020) 136 (Supplement 1): 19–21.

https://doi.org/10.1182/blood-2020-134612

Published: 2020

Journal Articles

Flotetuzumab As Salvage Therapy for Primary Induction Failure and Early Relapse Acute Myeloid Leukemia

Ibrahim Aldoss, MD, Geoffrey L Uy, MD, Norbert Vey, MD, Ashkan Emadi, MD, PhD, Peter H. Sayre, MDPhD, Roland B. Walter, MDPhDMS, Matthew C Foster, MD, Martha L. Arellano, MD, John E. Godwin, MD, Matthew J. Wieduwilt, MD PhD, Michael T. Byrne, DO, Laura C. Michaelis, MD, Patrick J. Stiff, MD, Matteo Giovanni Carrabba, MD, Patrice Chevalier, MD PhD, Emmanuel Gyan, MD PhD, Christian Recher, MD PhD, Anjali S Advani, MD, Martin Wermke, Harry P. Erba, Fabio Ciceri, MD, Geert Huls, MD PhD, Mojca Jongen-Lavrencic, MD PhD, Max S. Topp, MD, Antonio Curti, MDPhD, Farhad Ravandi, MBBS, Michael P. Rettig, PhD, John Muth, MS, Mary Beth Collins, Erin Timmeny, Kuo Guo, MSc, Jian Zhao, PhD, Kathy Tran, Patrick Kaminker, PhD, Priyanka Patel, PharmD, Ouiam Bakkacha, MD, Teia Curtis, Kenneth Jacobs, MD, Maya Kostova, PhD, Jennifer Seiler, PhD RAC, Bob Lowenberg, MDPhD, Sergio Rutella, MDPhDFRCPath, Ezio Bonvini, MD, Jan K Davidson-Moncada, MDPhD, John F. DiPersio, MD PhD

Blood (2020) 136 (Supplement 1): 16–18.

https://doi.org/10.1182/blood-2020-134576

Published: 2020

Journal Articles

Lintuzumab Ac-225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML: Interim Results of a Phase I Study

Sameem Abedin, MD, Guru Subramanian Guru Murthy, MBBS, Lyndsey Runaas, MD, Laura C. Michaelis, MD, Ehab L. Atallah, MD, Mehdi Hamadani, MD, Alexandra M. Harrington, MDMT(ASCP), Karen Carlson, MD

Blood (2019) 134 (Supplement_1): 2605.

https://doi.org/10.1182/blood-2019-122487

Published: 2019

Journal Articles

A Multisite Phase Ib Study of Pevonedistat, Azacitidine and Venetoclax (PAVE) for the Treatment of Subjects with Acute Myelogenous Leukemia (AML)

Guru Subramanian Guru Guru Murthy, MBBS, Scott H. Kaufmann, MD PhD, Aniko Szabo, PhD, Arielle Baim, Ashish Anshu, Alexander Hinman, Laura C. Michaelis, MD, Sameem Abedin, MD, Karen-Sue B. Carlson, MD PhD, Lyndsey Runaas, MD, Ehab L. Atallah, MD

Blood (2019) 134 (Supplement_1): 3837.

https://doi.org/10.1182/blood-2019-131728

Published: 2019

Journal Articles

Accrual Barriers and Detection of Early Toxicity Signal in Older Less-Fit Patients Treated with Azacitidine and Nivolumab for Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) in the SWOG 1612 Platform Randomized Phase II/III Clinical Trial

Annette E. Hay, Sarit Assouline, MD, Roland B. Walter, MD PhD MS, Richard F. Little, MD MPH, Anna Moseley, M.S., Sperling M Gail, MPH, CHES, Annie Im, MD, James M. Foran, MD, Jerald P. Radich, MD, Min Fang, MD PhD, Megan Othus, PhD, Harry P. Erba, MD PhD, Laura C. Michaelis, MD

Blood (2019) 134 (Supplement_1): 3905.

https://doi.org/10.1182/blood-2019-124320

Published: 2019

Journal Articles

The Prognostic Significance of Blast Aberrancies By Flow Cytometry in Low/Int Risk MDS

Kristen M Corrao, MD, Alexandra M. Harrington, MDMT(ASCP), Steven H. Kroft, MD, Laura C. Michaelis, MD, Karen-Sue B. Carlson, MD PhD, Lyndsey Runaas, MD, Ehab L. Atallah, MD, Sameem Abedin, MD

Blood (2019) 134 (Supplement_1): 5430.

https://doi.org/10.1182/blood-2019-130511

Published: 2019

Journal Articles

Phase I Study of Pracinostat in Combination with Gemtuzumab Ozogamicin (PraGO) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Talha Badar, MD, Guru Subramanian Guru Murthy, MD, Lyndsey Runaas, MD, Karen-Sue B. Carlson, MD PhD, Laura C. Michaelis, MD, Alexandra M. Harrington, MDMT(ASCP), Ehab L. Atallah, MD, Sameem Abedin, MD

Blood (2019) 134 (Supplement_1): 5068.

https://doi.org/10.1182/blood-2019-123237

Published: 2019

Journal Articles

Comparison of Salvage Chemotherapy Regimens in Relapsed/Refractory Acute Myeloid Leukemia

Muhammad Umair Mushtaq, MD, Sibgha Gull Chaudhary, MD, Laura C. Michaelis, MD, Karen-Sue B. Carlson, MD PhD, Sameem Abedin, MD, Lyndsey Runass, MD, Michael J. Fallon, PharmD, Alexandra M. Harrington, MD, Mark Juckett, MD, Aric C. Hall, MD, Ryan J. Mattison, MD, Ehab L. Atallah, MD, Guru Subramanian Guru Murthy, MBBS

Blood (2018) 132 (Supplement 1): 2708.

https://doi.org/10.1182/blood-2018-99-113764

Published: 2018

Journal Articles

Survival Advantage to Allogeneic Transplant in Patients with Myelofibrosis with Intermediate-1 or Higher DIPSS Score

Blood (2018) 132 (Supplement 1): 4288.

https://doi.org/10.1182/blood-2018-99-119002

Published: 2018

Journal Articles

Reducing Venous Thrombosis with Antithrombin Supplementation in Patients Undergoing Treatment for ALL with Asparaginase Based Regimens

Alexandra Rezazadeh, MD, Gemlyn George, MD, Nicole Pearl, PharmD, Cole McCoy, Felicia Zook, Benjamin Jung, Aschenbrenner Emilie, Mindy Waggoner, Sameem Abedin, MD, Lyndsey Runaas, MD, Laura C. Michaelis, MD, Karen-Sue B. Carlson, MD PhD, Lisa Baumann Kreuziger, MD MS, Ehab L. Atallah, MD

Blood (2018) 132 (Supplement 1): 1232.

https://doi.org/10.1182/blood-2018-99-114597

Published: 2018

Journal Articles

40 Is the New 50: Reducing the Need for Platelet Transfusions Prior to Lumbar Puncture in Patients with Hematologic Malignancies

Kristen M Corrao, MD, Laura C. Michaelis, MD, Lisa Baumann Kreuziger, MD MS, Karen-Sue B. Carlson, MD PhD, Sameem Abedin, MD, Elizabeth Malosh, MSN, RN, David Atkinson, Wenjing Shan, Stephen Quinet, MD MPH, Adrian P Umpierrez De Reguero, MD, DeLisle Julie, RN, MSN, Angela Treml, MD, Lyndsey Runaas, MD, Ehab L. Atallah, MD

Blood (2018) 132 (Supplement 1): 4837.

https://doi.org/10.1182/blood-2018-99-114264

Published: 2018

Journal Articles

Systematic Screening for Familial Leukemia Based on Somatic Genomic Profiling Results

Ensi Voshtina, DO, Arun K Singavi, MD, Amanda Jacquart, MS, CGC, Lyndsey Runaas, MD, Ehab L. Atallah, MD, Laura C. Michaelis, MD, Sameem Abedin, MD

Blood (2018) 132 (Supplement 1): 2253.

https://doi.org/10.1182/blood-2018-99-117020

Published: 2018

Journal Articles

A Phase 2 Dose-Confirmation Study of Oral ASTX727, a Combination of Oral Decitabine with a Cytidine Deaminase Inhibitor (CDAi) Cedazuridine (E7727), in Subjects with Myelodysplastic Syndromes (MDS)

Guillermo Garcia-Manero, MD, Elizabeth A. Griffiths, MD, Gail J. Roboz, MD, Lambert Busque, MD, Richard A. Wells, MD DPhil, Olatoyosi Odenike, MD, David P. Steensma, MD, Karen W.L. Yee, MD, Stefan Faderl, Philip C. Amrein, MD, Laura C. Michaelis, MD, Hagop M. Kantarjian, MD, Aram Oganesian, James N. Lowder, MD, Mohammad Azab, MD, Michael R. Savona, MD

Blood (2017) 130 (Supplement 1): 4274.

https://doi.org/10.1182/blood.V130.Suppl_1.4274.4274

Published: 2017

Journal Articles

Incidence and Outcomes of T-Cell Acute Lymphoblastic Leukemia (T-ALL) in United States

Guru Subramanian Guru Murthy, MBBS, Ravi Narra, MD, Binod Dhakal, MBBS, Mehdi Hamadani, MD, Laura C. Michaelis, MD, Ehab Atallah, MD

Blood (2017) 130 (Supplement 1): 2575.

https://doi.org/10.1182/blood.V130.Suppl_1.2575.2575

Published: 2017

Journal Articles

Recent Trends in the Incidence and Outcomes of Acute Promyelocytic Leukemia in United States

Guru Subramanian Guru Murthy, MBBS, Ravi Narra, MD, Binod Dhakal, MBBS, Mehdi Hamadani, MD, Laura C. Michaelis, MD, Ehab Atallah, MD

Blood (2017) 130 (Supplement 1): 2578.

https://doi.org/10.1182/blood.V130.Suppl_1.2578.2578

Published: 2017

Journal Articles

In Non-Selected Patients Treated for Influenza, Oseltamivir, a Glycosialidase Inhibitor, Demonstrates Improvement in Platelet Counts Compared to Time of Dosing, but Not over Baseline Levels

Sabina I. Cashin, BS, Melissa M. Lee-Sundlov, PhD, Karin M. Hoffmeister, MD, Laura C. Michaelis, MD

Blood (2017) 130 (Supplement 1): 3626.

https://doi.org/10.1182/blood.V130.Suppl_1.3626.3626

Published: 2017

Journal Articles

Successful Implementation of a Blood Management Program for Patients with Hematologic Malignancies

Kristen Corrao, MD, Kathleen Hemauer, MD, Tina Curtis, DNP, MBA, RN, NEA-BC, Dave Atkinson, Laura C. Michaelis, MD, Karen-Sue B. Carlson, MD PhD, Jerome Gottschall, MD, Ehab Atallah, MD

Blood (2017) 130 (Supplement 1): 2160.

https://doi.org/10.1182/blood.V130.Suppl_1.2160.2160

Published: 2017

Journal Articles

Preliminary Results from a Phase I Dose Escalation Trial of Ruxolitinib and the PI3Kδ Inhibitor TGR-1202 in Myelofibrosis

Tamara K Moyo, MD PhD, Andrew Sochacki, MD, Gregory D Ayers, MS, Michael T. Byrne, DO, Stephen A. Strickland, Sanjay R. Mohan, MD, Jill Harrison, Lynne D Berry, Channing V Dudley, Rachel Severs, Laura Dugger, Hari P. Miskin, MS, Amy Cavers, Peter Sportelli, Laura C Michaelis, MD, Ruben A. Mesa, MD, Michael R. Savona, MD

Blood (2016) 128 (22): 1125.

https://doi.org/10.1182/blood.V128.22.1125.1125

Published: 2016

NARROW

A Phase I Study of Lintuzumab Ac225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML

Immune Senescence and Exhaustion Correlate with Response to Flotetuzumab, an Investigational CD123×CD3 Bispecific Dart® Molecule, in Acute Myeloid Leukemia

Prophylactic Ruxolitinib for Cytokine Release Syndrome (CRS) in Relapse/Refractory (R/R) AML Patients Treated with Flotetuzumab

Flotetuzumab As Salvage Therapy for Primary Induction Failure and Early Relapse Acute Myeloid Leukemia

Lintuzumab Ac-225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML: Interim Results of a Phase I Study

A Multisite Phase Ib Study of Pevonedistat, Azacitidine and Venetoclax (PAVE) for the Treatment of Subjects with Acute Myelogenous Leukemia (AML)

Accrual Barriers and Detection of Early Toxicity Signal in Older Less-Fit Patients Treated with Azacitidine and Nivolumab for Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) in the SWOG 1612 Platform Randomized Phase II/III Clinical Trial

The Prognostic Significance of Blast Aberrancies By Flow Cytometry in Low/Int Risk MDS

Phase I Study of Pracinostat in Combination with Gemtuzumab Ozogamicin (PraGO) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Comparison of Salvage Chemotherapy Regimens in Relapsed/Refractory Acute Myeloid Leukemia

Survival Advantage to Allogeneic Transplant in Patients with Myelofibrosis with Intermediate-1 or Higher DIPSS Score

Reducing Venous Thrombosis with Antithrombin Supplementation in Patients Undergoing Treatment for ALL with Asparaginase Based Regimens

40 Is the New 50: Reducing the Need for Platelet Transfusions Prior to Lumbar Puncture in Patients with Hematologic Malignancies

Systematic Screening for Familial Leukemia Based on Somatic Genomic Profiling Results

A Phase 2 Dose-Confirmation Study of Oral ASTX727, a Combination of Oral Decitabine with a Cytidine Deaminase Inhibitor (CDAi) Cedazuridine (E7727), in Subjects with Myelodysplastic Syndromes (MDS)

Incidence and Outcomes of T-Cell Acute Lymphoblastic Leukemia (T-ALL) in United States

Recent Trends in the Incidence and Outcomes of Acute Promyelocytic Leukemia in United States

In Non-Selected Patients Treated for Influenza, Oseltamivir, a Glycosialidase Inhibitor, Demonstrates Improvement in Platelet Counts Compared to Time of Dosing, but Not over Baseline Levels

Successful Implementation of a Blood Management Program for Patients with Hematologic Malignancies

Preliminary Results from a Phase I Dose Escalation Trial of Ruxolitinib and the PI3Kδ Inhibitor TGR-1202 in Myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only